Biohaven To Report Fourth Quarter And Full Year 2020 Financial Results And Recent Business Developments On March 1, 2021 benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Biohaven Provides Update On ESG Practices
News provided by
Share this article
Share this article
NEW HAVEN, Conn., Feb. 8, 2021 /PRNewswire/ Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the Company or Biohaven ), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates today announced the advancement of several important steps that underscore the company s commitment to sound Environmental, Social and Governance ( ESG ) practices.
Maximizing long-term shareholder value and managing resources responsibly remains a key driving force for Biohaven s ESG strategy, with the Company dedicated to bringing innovative medicines forward for patients and to grow value for investors while maintaining an efficient and high-performing culture.
Published: Jan 07, 2021
NEW HAVEN, Conn., Jan. 7, 2021 /PRNewswire/ Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the Company or Biohaven ) today announced the acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc. ( Kleo ) that it did not previously own and the execution of an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab. In connection with these two transactions, Biohaven assumed Kleo s laboratory facilities located in Science Park in New Haven, Connecticut and formed Biohaven Labs to serve as the integrated chemistry and discovery research arm of Biohaven. Biohaven Labs will continue several existing Kleo discovery partnerships, including with the Bill and Melinda Gates Foundation for the development of a Hyperimmune Globulin Mimic (HGM) for COVID-19 and PeptiDream for the development of immuno-oncology therapeutics.
/PRNewswire/ Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that it has completed a focused analysis of the topline co-primary.